Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

被引：0
|
作者：
Christine R Jenkins
Paul W Jones
Peter MA Calverley
Bartolome Celli
Julie A Anderson
Gary T Ferguson
Julie C Yates
Lisa R Willits
Jörgen Vestbo
机构：
[1] Woolcock Institute of Medical Research,Division of Cardiac and Vascular Science, St George's
[2] University of London,undefined
[3] University Hospital,undefined
[4] St Elizabeth's Medical Centre,undefined
[5] GlaxoSmithKline (GSK),undefined
[6] Pulmonary Research Institute of Southeast Michigan,undefined
[7] GSK,undefined
[8] Wythenshawe Hospital,undefined
[9] Hvidovre Hospital,undefined
来源：
Respiratory Research | / 10卷
关键词：
Chronic Obstructive Pulmonary Disease; Chronic Obstructive Pulmonary Disease Patient; Fluticasone Propionate; Salmeterol; Severe Chronic Obstructive Pulmonary Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
    Burge, PS
    Calverley, PMA
    Jones, PW
    Spencer, S
    Anderson, JA
    Maslen, TK
    BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245): : 1297 - 1303
  • [12] The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide
    Wedzicha, Jadwiga A.
    Calverley, Peter M. A.
    Seemungal, Terence A.
    Hagan, Gerry
    Ansari, Zainab
    Stockley, Robert A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (01) : 19 - 26
  • [13] Inhaled salmeterol/fluticasone propionate - A review of its use in chronic obstructive pulmonary disease
    Fenton, C
    Keating, GM
    DRUGS, 2004, 64 (17) : 1975 - 1996
  • [14] Salmeterol/Fluticasone propionate - A review of its use in the treatment of chronic obstructive pulmonary disease
    Keating, Gillian M.
    McCormack, Paul L.
    DRUGS, 2007, 67 (16) : 2383 - 2405
  • [15] Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease
    Restrepo, Ruben D.
    Tate, Andrew
    Coquat, Joshua
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (14) : 1993 - 2002
  • [16] Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease
    Yasui, Hideki
    Inui, Naoki
    Fujisawa, Tomoyuki
    Karayama, Masato
    Enomoto, Noriyuki
    Nakamura, Yutaro
    Kuroishi, Shigeki
    Ohba, Hisano
    Yokomura, Koshi
    Sato, Jun
    Sato, Masaki
    Koshimizu, Naoki
    Toyoshima, Mikio
    Yamada, Takashi
    Masuda, Masafumi
    Shirai, Toshihiro
    Suda, Takafumi
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2018, 12
  • [17] Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease
    Du Yipeng
    Wang Wei
    Yang Wei
    He Bei
    中华医学杂志(英文版), 2014, (09) : 1613 - 1618
  • [18] Effects of Tiotropium and Salmeterol/Fluticasone Propionate on Airway Wall Thickness in Chronic Obstructive Pulmonary Disease
    Hoshino, Makoto
    Ohtawa, Junichi
    RESPIRATION, 2013, 86 (04) : 280 - 287
  • [19] Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease
    Du Yipeng
    Wang Wei
    Yang Wei
    He Bei
    CHINESE MEDICAL JOURNAL, 2014, 127 (09) : 1613 - 1618
  • [20] Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial
    Ayres, JG
    Price, MJ
    Efthimiou, J
    RESPIRATORY MEDICINE, 2003, 97 (03) : 212 - 220
12345